Integer Holdings clears US antitrust hurdle in $5.7bn KKR buyout
Integer Holdings Corporation has cleared a key regulatory milestone in its pending $5.7 billion acquisition by private equity firm KKR, after receiving early termination of the Hart-Scott-Rodino antitrust waiting period from US authorities.
The early termination, granted ahead of the standard 30-day HSR review window, removes one of the principal regulatory conditions standing between the deal and its close. Integer said it continues to expect the transaction to complete by the end of 2026.
The deal
Under the merger agreement signed on 2 August 2026, a KKR affiliate will acquire all outstanding shares of Integer for $127 per share in cash, representing a total enterprise value of approximately $5.7 billion. Integer stockholders of record as of 8 September 2026 will vote on the merger agreement at a virtual Special Meeting on 21 October 2026. The Integer board has unanimously recommended that stockholders vote in favour.
The transaction remains subject to stockholder approval and satisfaction of other customary closing conditions. No further regulatory approvals were identified in the release as outstanding.
Integer is one of the largest medical device CDMOs in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. Its brands include Greatbatch Medical and Lake Region Medical.
Market context
The KKR acquisition fits a pattern of significant private equity interest in the medical device contract manufacturing sector over recent years. CDMOs that serve implantable and active device categories occupy a structurally attractive position: long customer qualification cycles, high switching costs, and growing outsourcing penetration as original equipment manufacturers seek to reduce fixed-asset exposure.
Integer's scale and breadth across cardiac rhythm management and neuromodulation make it one of the more defensible assets in the CDMO segment. Neuromodulation, in particular, has seen sustained commercial growth as spinal cord stimulation and deep brain stimulation programmes expand, and several OEM customers in these areas are actively ramping device pipelines that will require manufacturing partners.
Private equity ownership is unlikely to disrupt Integer's operational relationships in the near term, though customers and employees will watch for post-close capital allocation decisions, particularly around capacity investment and potential portfolio rationalisation. KKR has a track record of buy-and-build strategies in healthcare services, so bolt-on acquisitions in adjacent device manufacturing niches are a plausible medium-term scenario.
With the antitrust condition now satisfied, attention shifts to the 21 October stockholder vote. At a price representing a meaningful premium to where Integer traded before the deal was announced, strong shareholder support is widely expected. Assuming the vote passes without complication, a Q4 2026 close remains on track.